Isis Fourth Quarter Strong, Antisense Rising
This article was originally published in The Pink Sheet Daily
Executive Summary
Cash from partners keeps company hardy as mipomersen Phase III continues.
You may also be interested in...
Isis Hits LDL Milestone In Bristol-Myers Squibb Deal
Firm talent-spots PCSK9 compound to the tune of $2 million.
Isis Hits LDL Milestone In Bristol-Myers Squibb Deal
Firm talent-spots PCSK9 compound to the tune of $2 million.
Genzyme, Isis Partner On Lipid Lowering Treatment Based On Antisense Technology
Genzyme calls mipomersen, currently in Phase III, a blockbuster after gaining rights in potential $1.9 billion deal.